*Fmc stock is down -85% in 5 years*
FMC looks like a deer caught in the headlights. Chinese and Indian generic manufacturers have squeezed its margins by aggressively flooding the market with cheap off-patent alternatives to its flagship insecticide, **Rynaxypyr (chlorantraniliprole)**. Generics now account for a large majority of the global crop protection market by value estimates. Estimates range from 70% to as high as 93% depending on the source and definition.
This massive supply surge collapsed global active ingredient prices and compressed FMC’s revenues, forcing the chemical producer into severe financial restructuring.
The company is therefore stuck in a survival conundrum after exhausting its capital armory. The B word, aka bankruptcy, has been mentioned quite often. The company’s capital structure and negative cash flow give skeptics reasons to doubt the 148-year-old company's ability to survive what amounts to its most severe existential crisis.
# The Brondeau’s Asymmetry:
I believe Brondeau’s return at the helm ought to be cheered by investors and seen as a valuable catalyst for contrarian rerating. The merger or sale of the company is back on the table. Pierre Brondeau is reputed for his ability to remove operational bottlenecks, deleverage balance sheets, and clean up enough for a valuation repricing. And he has moved quite swiftly:
* In May 2026, FMC priced a $1.2 billion offering of 8% senior secured notes due in 2031. Proceeds were earmarked to retire the company’s 3.2% note due in October 2026, repay debt, and for other general corporate purposes. This was a junk-rate coupon, but it bought time and pushed out maturities.
* In June 2026, FMC announced a $400M minority equity investment from Belgium’s Tessenderlo Group, for a 20% stake. In parallel, the company agreed to sell its India commercial business to Crystal Crop Protection for $252M with all proceeds allocated to debt reduction.
* The company also amended its revolving credit facility to include covenant relief, rescheduled a $200M prepayment under a strategic supply agreement with Corteva, and signed a $114M sale-and-leaseback of its Newark, Delaware property.
All combined, these actions represent a credible path to reducing debt by up to $1 billion. This might not solve the company’s problems entirely, but it marks a significant positive step forward to push bankruptcy off the table and give Brondeau enough leeway and room to operate.
He was the architect of [FMC -6.09%↓](https://substack.com/search/%24FMC) previous transformation. There is no better candidate to clean up the current mess and potentially get a decent takeover bid.
`The asymmetry is clear: the market is pricing FMC as an extreme distress case. But with Pierre Brondeau back at the helm, I believe the bankruptcy risks are overblown and the upside multi-baggers completely ignored by general consensus.`
# The Valuation pessimism.
FMC trades at a P/B of 0.8x, below book value, and at an EV/EBITDA that is roughly 1/2 of the industry average. The combination of dividend cuts, debt load, generic competition, the patent cliff, and negative cash flow has led many analysts to rate the company at a high probability of bankruptcy.
But the market is underweighting Brondeau’s recent actions and ignoring the aggressive transformation. The facts are clear: the agrochemical industry will be forced to consolidate to compete with Asian generics.
The Tessenderlo investment and the company’s bond refinancing have bought 2-3 years of runway. The India subs sale and other asset divestitures are generating real cash for deleveraging.
A strategic buyer, likely a larger Agrochemical firm interested in FMC’s patent portfolio—including Rynaxypyr, CYazypyr, and the diamide platform—along with manufacturing capabilities and Latin American distribution, might purchase the company at a distressed price of $25 to $35 per share. Well below its replacement cost. Private equity is also an option if the debt can be further reduced and the cash flow profile stabilized.
`The market consensus overlooks that the downside is already priced in, while the upside is priced at near-zero probability. The optionality lies in exploiting this valuation mispricing.`
**At 8.1x, FMC trades below its peers’ EV/EBITDA average of 12x. The agrochemical and fertilizer sector saw M&A multiples averaging 14-18x for high-growth and strategically critical assets.** For a distressed but valuable entity such as FMC, a buyer should nominally bid up to 12x EBITDA. With Pierre Brondeau's premium included, investors can be confident in an experienced operator who knows exactly what his assets are worth and in an exec with deep relationships across the agrochemical industry who can facilitate a smooth transition.
Most investors and analysts have not fully priced in Pierre Brondeau's “unique premium”. Without him, the company would lack a clear restructuring plan, potentially setting the stage for bankruptcy within 12-18 months. Brondeau's presence alone represents a huge margin of credibility that has yet to be priced in.
# Conclusion: A risky optionality bet selling at extreme discount.
FMC Corporation is facing its worst existential crisis. The market consensus has completely abandoned any hope for its future, with many experts comparing its current situation to the fate of drug manufacturers’ patent-expiration crisis in 2016.
The rehiring of Pierre Brondeau represents a premium hedge against the loud bankruptcy noise. That alone constitutes a baseline that the company stock price misses. Brondeau’s restructuring expertise and ongoing, swift debt-reduction push are equally mispriced and ignored in analysts’ reports.
To be fair, FMC is not a clear-cut contrarian discount selling below cash flow or Net Asset. FMC is a seriously distressed entity trying to clean up decades of capital misallocation and debt accumulation for a profitable sum-of-the-parts sale to a deep-pocketed competitor.
Consequently, I will not directly hold the equity itself but mitigate the stock's current risk profile by buying its deeply discounted out-of-the-money call option expiring in 2028.
Why? Because Brondeau is 68 years old, and FMC’s own proxy disclosures show the board explicitly wrestling with succession terms tied to his tenure. Age and energy are non-negligible factors given the scale of energy and effort required to turn what amounts to a sinking ship.
Is Pierre Brondeau the last CEO of an independent FMC Corporation? Much of the proxies language points to that. For a contrarian, risk-tolerant hedger, 2 years of optionality margins of error is a safe bet against extreme uncertainty while maintaining a premium discount in case the turnaround or sale pans out.
*Not investment advice. Always consult a trusted investment advisor before buying or selling financial securities. Wall Street is not your Friend.*
